Skip to main content
. 2020 Oct 13;29(4):207–211. doi: 10.1136/ejhpharm-2020-002374

Table 4.

Multivariate analyses results

OR (95% CI) P value
Discontinuations due to AEs
 Female gender 2.610 (1.327 to 5.133) 0.005
Discontinuations due to NPAEs
 Previous documented psychiatric disorders 4.782 (1.190 to 19.220) 0.027

AEs, adverse events; NPAEs, neuropsychiatric adverse events.